Vyome Holdings, Inc. — filing identity discrepancy
The supplied filing is ReShape Lifesciences Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2024, not a filing identified as Vyome Holdings, Inc. The summary below reflects ReShape’s filing. Dollar amounts are in thousands unless otherwise stated.
Business context and reporting period
ReShape sells the Lap-Band adjustable gastric band system and accessories, primarily in the United States, Australia, and Europe. The Obalon Balloon System and Diabetes Bloc-Stim Neuromodulation (DBSN) generated no revenue; DBSN remains in development. The company said it is shifting toward a metrics-driven, scalable model using digital lead generation and re-engagement.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $1,944 | $2,287 |
| Gross profit / margin | $1,165 / 59.9% | $1,224 / 53.5% |
| Operating expenses | $3,375 | $6,855 |
| Operating loss | $(2,210) | $(5,631) |
| Net loss | $(2,193) | $(2,662) |
| Adjusted EBITDA (non-GAAP) | $(2,131) | $(5,338) |
| Cash used in operating activities | $(2,072) | $(5,061) |
At March 31, 2024, cash and cash equivalents were $2,379, restricted cash was $100, and accounts receivable was $1,566. Net working capital was approximately $4.4 million. Total liabilities were $3,697, including $239 of operating lease liabilities and a $51 warrant liability. The filing does not report conventional borrowings or a separate debt balance. Cash, cash equivalents, and restricted cash totaled $2,479, down $2,080 during the quarter; there was no financing cash inflow in Q1 2024.
Material changes versus the prior comparable period
- Revenue fell 15.0% year over year, primarily from lower sales volume; management attributed the pressure mainly to GLP-1 pharmaceutical weight-loss alternatives. U.S. revenue declined 10.8%, while Australia and Europe declined 35.0% and 34.9%, respectively.
- Gross margin rose to 59.9% from 53.5%, which management attributed mainly to reduced overhead, particularly payroll following late-2023 staff reductions. Gross profit itself decreased slightly.
- Operating expenses fell 50.8%. Sales and marketing decreased 53.3%, and general and administrative expenses decreased 55.6%; research and development increased 6.8%.
- Net loss narrowed, but the comparison includes a much larger noncash warrant fair-value gain in Q1 2023 ($2,965 versus $21 in Q1 2024). Operating loss and adjusted EBITDA also improved, reflecting lower expenses.
- Cash used in operations decreased to $2,072 from $5,061. The 2023 period included $10,201 of net financing proceeds from a public offering; Q1 2024 had no financing proceeds.
Outlook, risks, contingencies, and unusual items
- Going concern and funding: Management stated available resources are insufficient to fund current operations for more than 12 months from the filing date, raising substantial doubt about the company’s ability to continue as a going concern. If additional cash is not raised and plans do not develop, management expected cash to run out during Q3 2024 at the then-current burn rate. Financing availability is not assured; management’s plans do not alleviate the substantial doubt.
- Operating plans: Priorities include growing Lap-Band sales, introducing Lap-Band 2.0 FLEX, continuing DBSN development, pursuing strategic partnerships and licensing, and evaluating strategic M&A alternatives. No quantified revenue or earnings guidance is provided.
- Legal matter: Cowen obtained a judgment for a $1.35 million fee, interest, and $675,000 of attorneys’ fees. The filing says the judgment and interest were paid; $200,000 of attorneys’ fees was accrued at quarter-end and paid in April 2024. The company reported no other known litigation expected to have a material adverse effect.
- Internal controls: Management concluded internal control over financial reporting was not effective due to material weaknesses, including insufficient accounting and finance resources, journal-entry approval and segregation-of-duties issues, IT access/security oversight, and weaknesses in inventory, tax, and purchase-accounting controls. Remediation is underway.
- Potential dilution: The filing reports 15,598,390 warrants excluded from diluted loss per share as anti-dilutive, alongside stock options and other awards. The common stock count was approximately 23.46 million at March 31, 2024.
Important facts for investors to verify
- Confirm the issuer: the supplied 10-Q is ReShape Lifesciences Inc. (Nasdaq: RSLS), not Vyome Holdings, Inc.
- Check subsequent financing, cash burn, and whether the company secured resources to address the stated Q3 2024 cash-runway risk.
- Track Lap-Band sales trends and the effect of GLP-1 alternatives, particularly across the U.S., Australia, and Europe.
- Monitor progress on Lap-Band 2.0 FLEX, DBSN development, and strategic partnership or licensing plans, none of which has quantified guidance in this filing.
- Review remediation of the disclosed material weaknesses and the potential dilution and terms associated with outstanding warrants.